Why CNS Pharmaceuticals Shares Are Getting Hammered

CNS Pharmaceuticals, Inc CNSP shares are trading lower by 33.4% to $0.14 during Monday’s session after the company announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4. This move aims to increase the share price and meet Nasdaq’s minimum share price requirement.

In the reverse split, every 50 shares of common stock will be consolidated into one share. Warrants, equity-based awards, and other equity rights will be adjusted accordingly. Fractional shares will not be issued; instead, any fractional share entitlement will be rounded up to the nearest whole share.

The par value of the common stock remains at $0.001 per share, and the authorized shares stay at 300 million. The reverse split will uniformly affect all stockholders without changing any stockholder’s ownership percentage, except for rounding adjustments.

See Also: Nvidia’s Gamma Squeeze: Stock Skyrockets On Options Market Frenzy

Should I Sell My CNSP Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of CNS Pharma have decreased by 93.88% in the past year. An investor who bought shares of CNS Pharma at the beginning of the year would take a loss of $1.04 per share if they sold it today. The stock has fallen 28.17% over the past month, meaning an investor who bought shares on May. 1 would see a capital loss of $0.07.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. CNS Pharma stock currently has an RSI of 55.04, indicating neutral conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

CNSP has a 52-week high of $2.91 and a 52-week low of $0.14.